These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
123. Specificity of Retroviral Proteinases Based on Substrates Containing Tyrosine and Proline at the Site of Cleavage. Tözsér J Pathol Oncol Res; 1997; 3(2):142-146. PubMed ID: 11173643 [TBL] [Abstract][Full Text] [Related]
125. Current knowledge and future prospects for the use of HIV protease inhibitors. Moyle G; Gazzard B Drugs; 1996 May; 51(5):701-12. PubMed ID: 8861542 [TBL] [Abstract][Full Text] [Related]
126. Efficiency of nanoparticles as a carrier system for antiviral agents in human immunodeficiency virus-infected human monocytes/macrophages in vitro. Bender AR; von Briesen H; Kreuter J; Duncan IB; Rübsamen-Waigmann H Antimicrob Agents Chemother; 1996 Jun; 40(6):1467-71. PubMed ID: 8726020 [TBL] [Abstract][Full Text] [Related]
127. Viral dynamics in vivo: limitations on estimates of intracellular delay and virus decay. Herz AV; Bonhoeffer S; Anderson RM; May RM; Nowak MA Proc Natl Acad Sci U S A; 1996 Jul; 93(14):7247-51. PubMed ID: 8692977 [TBL] [Abstract][Full Text] [Related]
128. [HIV: less resistance due to combined treatment]. Dtsch Med Wochenschr; 1996 Dec; 121(49):A47-8. PubMed ID: 8998914 [No Abstract] [Full Text] [Related]
129. HIV-protease inhibitors. Flexner C N Engl J Med; 1998 Apr; 338(18):1281-92. PubMed ID: 9562584 [No Abstract] [Full Text] [Related]